Conformal integration of electronics with soft, irregular organ topologies remains challenging, as tissue-like platforms with bulky dimensions ranging from a few millimetres to several hundred micrometres result in incomplete signal acquisition and chronic tissue compression. Although ultrathin nanoscale devices have recently been developed to address these challenges, they involve complex and delicate handling processes that… Continue reading #Hydrogel –elastomer-based conductive nanomembranes for soft #bioelectronics
#Fasting boosts #breast cancer therapy efficacy via glucocorticoid activation
The majority of breast cancers are driven by oestrogen receptor-α (ERα) activation, and endocrine therapy represents the mainstay treatment for these patients1. However, resistance is common and tumours often progress after years of endocrine suppression2. Periodic fasting enhances the efficacy of standard endocrine therapy and delays acquired drug resistance, although the underlying mechanisms remain unclear3.… Continue reading #Fasting boosts #breast cancer therapy efficacy via glucocorticoid activation
#Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Cholangiocarcinoma (CCA) is a cancer that originates within the bile ducts. Traditionally considered to be a rare neoplasm, increased awareness of CCA alongside advancements in diagnosis and the rising prevalence of certain risk factors have contributed to a global increase in incidence and mortality. CCAs are highly heterogeneous from the clinical, histomorphological and molecular perspectives… Continue reading #Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Early shift to oral #antibiotic treatment for pyogenic vertebral #osteomyelitis (SAVE): study protocol for an open label, non-inferiority, nation-wide randomized controlled clinical trial
BackgroundThe current Danish National Guideline (DNG) for treatment of pyogenic vertebral osteomyelitis (PVO) recommends 6 weeks antibiotic (AB) treatment, with a 2-week intravenous (IV) AB lead-in followed by 4 weeks oral AB for uncomplicated PVO, and 12 weeks AB treatment with a 4-week IV AB lead-in followed by 8 weeks oral AB for complicated PVO.The… Continue reading Early shift to oral #antibiotic treatment for pyogenic vertebral #osteomyelitis (SAVE): study protocol for an open label, non-inferiority, nation-wide randomized controlled clinical trial
Efficacy and safety of #metformin versus #empagliflozin on chronic #kidney disease progression (MET-EMPA-CKD): a randomized controlled trial
Chronic kidney disease (CKD) is a devastating progressive condition accompanied with high morbidity and mortality rates. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have recently proven their renoprotective effects, whereas evidence for metformin remains limited but suggestive of potential benefit. This study aimed at comparing the efficacy and safety of metformin versus empagliflozin, a SGLT2 inhibitor, on retarding… Continue reading Efficacy and safety of #metformin versus #empagliflozin on chronic #kidney disease progression (MET-EMPA-CKD): a randomized controlled trial
Supplementation with #short-chain fatty acids and a #prebiotic improves clinical outcome in #Parkinson’s disease: a randomized double-blind prospective study
Background: Parkinson's disease is associated with a dysbiotic, proinflammatory gut microbiome, disruptions to intestinal barrier functions, and immunological imbalance. Microbiota-produced short-chain fatty acids, such as propionic and butyric acid promote gut barrier integrity and immune regulation, but their impact on Parkinson's disease pathology remains mostly unknown.Methods: In a randomized double-blind prospective study, 72 people with… Continue reading Supplementation with #short-chain fatty acids and a #prebiotic improves clinical outcome in #Parkinson’s disease: a randomized double-blind prospective study
The effects of glucagon-like peptide-1 receptor agonists (#GLP1-RAs ) on #alcohol -related outcomes: a systematic review and meta-analysis
Objective: To evaluate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on alcohol-related outcomes in adults with or without alcohol use disorder (AUD).Methods: A systematic review and meta-analysis following PRISMA guidelines searched PubMed, Embase, and Cochrane Library up to May 3, 2025. Eligible studies included randomized controlled trials (RCTs) and observational studies assessing GLP-1RAs (e.g.,… Continue reading The effects of glucagon-like peptide-1 receptor agonists (#GLP1-RAs ) on #alcohol -related outcomes: a systematic review and meta-analysis
ReviewPractical guidance for navigating #buprenorphine discontinuation
Approximately 4.8 million people in the United States had opioid use disorder in 2024, with more than one hundred thousand experiencing an overdose death. Despite the established benefits of buprenorphine on morbidity and mortality, many patients may express an interest in discontinuing their medications for various reasons, including stigma surrounding addiction. There are limited studies… Continue reading ReviewPractical guidance for navigating #buprenorphine discontinuation
ReviewManagement of Refractory #Hepatic #Encephalopathy
Refractory hepatic encephalopathy (HE) is a complex and debilitating disorder that significantly impacts healthcare utilization and causes lingering cognitive defects that can at times be permanent. It represents an economically and emotionally costly entity for patients and caregivers. Precipitants and pathogenic factors of this disease are numerous, cumulative, and often present with subtle features. A… Continue reading ReviewManagement of Refractory #Hepatic #Encephalopathy
2 Medical News 